New combo tackles kidney cancer after immunotherapy fails
NCT ID NCT07460206
First seen Mar 15, 2026 · Last updated May 19, 2026 · Updated 7 times
Summary
This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced kidney cancer (clear cell type) whose disease got worse after prior immunotherapy. About 108 adults will receive the treatment to see if it shrinks tumors or delays cancer growth. The goal is to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCRCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.